IOP lowered with trab and combination trab

Article

IOP is successfully reduced with both trabeculectomy and combined trabeculotomy-trabeculectomy with mitomycin C in children with glaucoma.

IOP is successfully reduced with both trabeculectomy and combined trabeculotomy-trabeculectomy with mitomycin C in children with glaucoma.

The retrospective, comparative study, led by Dr Peter A. Netland, Department of Ophthalmology (SDL), University of North Carolina, Chapel Hill, North Carolina, USA, included 40 eyes of 33 glaucoma patients.

Trabeculectomy was performed on 17 eyes (Group 1) and 23 eyes underwent combined trabeculotomy-trabeculectomy (Group 2), with mitomycin C administered to all patients. Successful surgery was defined if IOP was 21 mmHg or less and greater than 5 mmHg without additional surgery.

No significant difference in mean IOP reduction was found between the groups during follow-up. There was a higher success rate after surgery in group 2, compared to group 1. There were five treatment failures in group 1 and two in group 2. The failures were caused increased IOP or hypotony and there were no complications observed.

Both procedures are equally effective in lowering average IOP in children with glaucoma, but combined trabeculotomy-trabeculectomy was linked to greater long-term successful outcomes.

More detailed information may be found at the Journal of Paediatric Ophthalmology and Strabismus, click here

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.